Sab biotherapeutics reports full year 2023 operating and financial results

Sioux falls, sd , march 29, 2024 (globe newswire) -- sab biotherapeutics reports full year 2023 operating and financial results march 29, 2024 sab-142 phase 1 trial on track for data release during 2024 completed financing for up to $110 million with leading life science investors cash and equivalents of $56.6 million as of december 31, 2023 company expects its cash and equivalents, with exercise of tranche b warrants, will fund operations into 2026 sioux falls, sd march 29, 2024 (globenewswire)—sab biotherapeutics, inc. (nasdaq:sabs), (“sab” or “the company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced its financial results for the fourth quarter of 2023 in addition to its full year financial results for the fiscal year ended december 31, 2023, and reported on recent accomplishments and expected upcoming milestones. “during 2023, we significantly changed the direction of our company to focus on sab-142, our innovative, human anti-thymocyte immune globulin for the prevention of progression of t1d” stated samuel j.
SABS Ratings Summary
SABS Quant Ranking